← Back to NATCO Pharma Ltd. overview
NATCO Pharma Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹4,412 cr | ₹1,885 cr | ₹105.26 | ₹8,631 cr | ₹7,607 cr | 24.79% | 29.27% | 0.04x | 42.74% |
| FY2024 | ₹3,979 cr | ₹1,388 cr | ₹77.34 | ₹6,906 cr | ₹5,853 cr | 23.72% | 27.08% | 0.06x | 34.89% |
| FY2023 | ₹2,697 cr | ₹715 cr | ₹39.18 | ₹5,657 cr | ₹4,874 cr | 14.68% | 17.26% | 0.04x | 26.52% |
| FY2022 | ₹1,905 cr | ₹170 cr | ₹9.32 | ₹5,109 cr | ₹4,264 cr | 3.99% | 4.59% | 0.1x | 8.92% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.